Is LKFT or PROK more profitable?

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A ProKidney -8,131.50% N/A -21.39%

Does the media refer more to OCUL or PROK?

In the previous week, Ocular Therapeutix had 10 more articles in the media than ProKidney. MarketBeat recorded 13 mentions for Ocular Therapeutix and 3 mentions for ProKidney. Ocular Therapeutix's average media sentiment score of 0.52 beat ProKidney's score of -0.10 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ANIP or PROK?

In the previous week, ANI Pharmaceuticals had 4 more articles in the media than ProKidney. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 3 mentions for ProKidney. ANI Pharmaceuticals' average media sentiment score of 0.84 beat ProKidney's score of -0.10 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PROK or TYRA?

In the previous week, Tyra Biosciences had 8 more articles in the media than ProKidney. MarketBeat recorded 11 mentions for Tyra Biosciences and 3 mentions for ProKidney. Tyra Biosciences' average media sentiment score of 0.25 beat ProKidney's score of -0.10 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to STOK or PROK?

In the previous week, Stoke Therapeutics had 29 more articles in the media than ProKidney. MarketBeat recorded 32 mentions for Stoke Therapeutics and 3 mentions for ProKidney. Stoke Therapeutics' average media sentiment score of 0.16 beat ProKidney's score of -0.10 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 6 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

ProKidney (PROK) Competitors

$1.67 +0.04 (+2.45%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.66 -0.01 (-0.90%)

As of 04:10 AM Eastern

Compare

PROK vs. LKFT, OCUL, ANIP, TYRA, and STOK

Should you buy ProKidney stock or one of its competitors? MarketBeat compares ProKidney with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProKidney include Lakefront Biotherapeutics American Depositary Shares (LKFT), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Tyra Biosciences (TYRA), and Stoke Therapeutics (STOK).

How does ProKidney compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
ProKidney	-8,131.50%	N/A	-21.39%

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $34.33, indicating a potential upside of 31.65%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 618.56%. Given ProKidney's stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than ProKidney. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.65	$363.05M	-$1.41	N/A
ProKidney	$890K	566.79	-$68.99M	-$0.53	N/A

In the previous week, ProKidney had 1 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 3 mentions for ProKidney and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.62 beat ProKidney's score of -0.10 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Lakefront Biotherapeutics American Depositary Shares on 10 of the 15 factors compared between the two stocks.

How does ProKidney compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Ocular Therapeutix has a net margin of -579.10% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
ProKidney	-8,131.50%	N/A	-21.39%

ProKidney has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	35.93	-$265.94M	-$1.42	N/A
ProKidney	$890K	566.79	-$68.99M	-$0.53	N/A

Ocular Therapeutix has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

Ocular Therapeutix currently has a consensus price target of $25.75, suggesting a potential upside of 202.94%. ProKidney has a consensus price target of $12.00, suggesting a potential upside of 618.56%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.69
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ocular Therapeutix had 10 more articles in the media than ProKidney. MarketBeat recorded 13 mentions for Ocular Therapeutix and 3 mentions for ProKidney. Ocular Therapeutix's average media sentiment score of 0.52 beat ProKidney's score of -0.10 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.

How does ProKidney compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

ANI Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

ANI Pharmaceuticals has a net margin of 9.98% compared to ProKidney's net margin of -8,131.50%. ANI Pharmaceuticals' return on equity of 27.51% beat ProKidney's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
ProKidney	-8,131.50%	N/A	-21.39%

ANI Pharmaceuticals currently has a consensus price target of $105.00, indicating a potential upside of 31.45%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 618.56%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

ANI Pharmaceuticals has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	2.06	$78.34M	$3.95	20.22
ProKidney	$890K	566.79	-$68.99M	-$0.53	N/A

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ANI Pharmaceuticals had 4 more articles in the media than ProKidney. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 3 mentions for ProKidney. ANI Pharmaceuticals' average media sentiment score of 0.84 beat ProKidney's score of -0.10 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ANI Pharmaceuticals beats ProKidney on 12 of the 17 factors compared between the two stocks.

How does ProKidney compare to Tyra Biosciences?

ProKidney (NASDAQ:PROK) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

ProKidney has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	566.79	-$68.99M	-$0.53	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

In the previous week, Tyra Biosciences had 8 more articles in the media than ProKidney. MarketBeat recorded 11 mentions for Tyra Biosciences and 3 mentions for ProKidney. Tyra Biosciences' average media sentiment score of 0.25 beat ProKidney's score of -0.10 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

51.6% of ProKidney shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ProKidney has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

ProKidney currently has a consensus target price of $12.00, suggesting a potential upside of 618.56%. Tyra Biosciences has a consensus target price of $46.90, suggesting a potential upside of 82.42%. Given ProKidney's higher probable upside, equities analysts plainly believe ProKidney is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Tyra Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Tyra Biosciences	N/A	-48.07%	-44.73%

Summary

ProKidney beats Tyra Biosciences on 9 of the 15 factors compared between the two stocks.

How does ProKidney compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Stoke Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

In the previous week, Stoke Therapeutics had 29 more articles in the media than ProKidney. MarketBeat recorded 32 mentions for Stoke Therapeutics and 3 mentions for ProKidney. Stoke Therapeutics' average media sentiment score of 0.16 beat ProKidney's score of -0.10 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	6 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Stoke Therapeutics presently has a consensus target price of $43.00, indicating a potential upside of 34.67%. ProKidney has a consensus target price of $12.00, indicating a potential upside of 618.56%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

51.6% of ProKidney shares are held by institutional investors. 9.6% of Stoke Therapeutics shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Stoke Therapeutics has higher revenue and earnings than ProKidney. Stoke Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$27.59M	72.08	-$6.89M	-$3.34	N/A
ProKidney	$890K	566.79	-$68.99M	-$0.53	N/A

Stoke Therapeutics has a net margin of -753.60% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
ProKidney	-8,131.50%	N/A	-21.39%

Summary

ProKidney beats Stoke Therapeutics on 10 of the 17 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROK vs. The Competition

Export

Metric	ProKidney	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$492.36M	$3.57B	$6.86B	$12.98B
Dividend Yield	N/A	3.77%	2.60%	9.79%
P/E Ratio	-3.15	7.68	280.40	25.25
Price / Sales	566.79	1,179.03	562.13	77.61
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	-0.50	17.07	12.94	6.09
Net Income	-$68.99M	-$12.52M	$3.49B	$347.95M
7 Day Performance	5.70%	2.31%	2.42%	3.11%
1 Month Performance	-16.08%	-5.14%	-2.87%	-2.99%
1 Year Performance	-42.01%	52.14%	75.29%	20.51%

ProKidney Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROK ProKidney	1.6923 of 5 stars	$1.67 +2.5%	$12.00 +618.6%	-47.5%	$492.36M	$890K	N/A	3	Upcoming Earnings
LKFT Lakefront Biotherapeutics American Depositary Shares	2.2129 of 5 stars	$27.72 -1.5%	$34.33 +23.9%	-20.9%	$1.86B	$1.26B	N/A	1,310	Upcoming Earnings Analyst Downgrade
OCUL Ocular Therapeutix	2.7733 of 5 stars	$8.36 -1.1%	$25.11 +200.4%	-29.2%	$1.85B	$51.95M	N/A	230	Earnings Report Analyst Forecast
ANIP ANI Pharmaceuticals	4.319 of 5 stars	$81.78 +0.9%	$105.00 +28.4%	+21.3%	$1.84B	$883.37M	20.70	600	Upcoming Earnings
TYRA Tyra Biosciences	2.721 of 5 stars	$31.11 +0.7%	$47.00 +51.1%	+124.5%	$1.84B	N/A	N/A	20	News Coverage Earnings Report Upcoming Earnings Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROK) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Competitors

PROK vs. LKFT, OCUL, ANIP, TYRA, and STOK

How does ProKidney compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does ProKidney compare to Ocular Therapeutix?

Summary

How does ProKidney compare to ANI Pharmaceuticals?

Summary

How does ProKidney compare to Tyra Biosciences?

Summary

How does ProKidney compare to Stoke Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Competitors

PROK vs. LKFT, OCUL, ANIP, TYRA, and STOK

How does ProKidney compare to Lakefront Biotherapeutics American Depositary Shares?

Which has more risk and volatility, LKFT or PROK?

Do institutionals & insiders believe in LKFT or PROK?

Is LKFT or PROK more profitable?

Do analysts recommend LKFT or PROK?

Which has higher earnings & valuation, LKFT or PROK?

Does the media prefer LKFT or PROK?

Summary

How does ProKidney compare to Ocular Therapeutix?

Is OCUL or PROK more profitable?

Which has higher valuation and earnings, OCUL or PROK?

Which has more volatility & risk, OCUL or PROK?

Do analysts prefer OCUL or PROK?

Do institutionals and insiders have more ownership in OCUL or PROK?

Does the media refer more to OCUL or PROK?

Summary

How does ProKidney compare to ANI Pharmaceuticals?

Which has more volatility and risk, ANIP or PROK?

Is ANIP or PROK more profitable?

Do analysts prefer ANIP or PROK?

Which has preferable valuation and earnings, ANIP or PROK?

Do insiders & institutionals hold more shares of ANIP or PROK?

Does the media prefer ANIP or PROK?

Summary

How does ProKidney compare to Tyra Biosciences?

Which has stronger valuation and earnings, PROK or TYRA?

Does the media favor PROK or TYRA?

Do institutionals and insiders have more ownership in PROK or TYRA?

Which has more volatility & risk, PROK or TYRA?

Do analysts recommend PROK or TYRA?

Is PROK or TYRA more profitable?

Summary

How does ProKidney compare to Stoke Therapeutics?

Which has more volatility & risk, STOK or PROK?

Does the media refer more to STOK or PROK?

Do analysts rate STOK or PROK?

Do institutionals & insiders believe in STOK or PROK?

Which has preferable earnings and valuation, STOK or PROK?

Is STOK or PROK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools